Brokerages Set Roche Holding AG (OTCMKTS:RHHBY) Price Target at $51.50

Shares of Roche Holding AG (OTCMKTS:RHHBY) have earned a consensus rating of “Hold” from the eleven research firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $51.50.

Several analysts recently issued reports on RHHBY shares. Wolfe Research reaffirmed an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Morgan Stanley raised shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective for the company in a research note on Friday, April 24th. TD Cowen reaffirmed a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. Argus raised shares of Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Finally, Citigroup initiated coverage on shares of Roche in a research note on Tuesday, January 27th. They issued a “buy” rating for the company.

Roche Trading Up 0.0%

Shares of OTCMKTS RHHBY opened at $51.10 on Friday. Roche has a 12-month low of $37.51 and a 12-month high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average of $50.64 and a 200 day moving average of $51.46.

Institutional Trading of Roche

Several hedge funds have recently made changes to their positions in RHHBY. Canopy Partners LLC grew its stake in shares of Roche by 4.9% in the 3rd quarter. Canopy Partners LLC now owns 7,580 shares of the company’s stock valued at $317,000 after buying an additional 352 shares during the period. Boston Common Asset Management LLC grew its stake in shares of Roche by 1.9% in the 3rd quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock valued at $15,049,000 after buying an additional 6,720 shares during the period. Oakworth Capital Inc. purchased a new stake in shares of Roche in the 3rd quarter valued at approximately $57,000. Sentinel Trust Co. LBA purchased a new stake in shares of Roche in the 3rd quarter valued at approximately $878,000. Finally, Altrius Capital Management Inc grew its stake in shares of Roche by 4.0% in the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock valued at $8,290,000 after buying an additional 7,659 shares during the period.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.